In a message dated 5/6/2005 9:18:29 AM Eastern Daylight Time, ZBirdBrain
writes:

> There is obviously a problem with many vets failing to provide Client
> Information Sheets (CIS) and many seem to be having difficulty informing
> their
> clients about the benefits and risks associated with vaccines and many other
>
> veterinary pharmaceutical products. When Kris Christine gave her testimony
> in an
> effort to pass the Full Disclosure bill in Maine there were vets who claimed
> that
> they do provide that information to their clients and they didn't need a law
>
> to force them to do something they already do. Based on my own experiences I
>
> think those vets are extremely rare.
>
> In an effort to support pet advocates like Kris a survey has been prepared.
> Completed surveys will be filed by state and by product. They will be given
> to
> pet advocates and to Politicians as needed. We are hopeful this information
> will be help to prove to legislators that although a few vets claim to be
> informing their clients far more are neglecting and often blatantly refusing
> to do
> so. I ask that any of you who were not given this information please fill
> out
> our survey. You can obtain a copy by contacting us at
> ClientInfoSheet@...
>
> Your survey information could help pet advocates to get legislation passed
> that will protect our pets. If anyone has any correspondence from
> pharmaceutical
> companies stating that they furnish CIS to the vets if you would share that
> correspondence it would be very helpful too.
>
> Thank you,
> Deb
>

Deb:

THANK YOU! This survey is very important and I encourage everyone to
participate! Please everyone, share this with your fellow pet owners/guardians.

Some background on the Rimadyl Client Information Sheet:

December 1999 CVM Update on Rimadyl:
http://www.fda.gov/cvm/CVM_Updates/rimadyl2.html

Pfizer's Dear Doctor Letter - March 2000 - http://www.fda.gov/cvm/4045.htm

QUOTE:
North AmericanRegion
Animal Health Group
Pfizer Inc
812 Springdale Drive
Exton, PA 19341
____________________________
Animal Health

March 9, 2000

Dear Doctor,The purpose of this letter is to inform you of several changes
Pfizer will implement in 2000 regarding Rimadyl® (carprofen). Similar to trends
observed in human medicine, the veterinary community is finding that their
clients are becoming more educated on medical conditions. These educated
consumers are demanding more detailed explanations and comprehensive product
information than they have in the past. The following outlines several ways
Pfizer
Animal Health will take the lead to help you facilitate appropriate risk benefit
communication with your clients when prescribing Rimadyl. This letter also
contains important medical/safety information and is part of an ongoing
commitment
of Pfizer Animal Health and the FDA-CVM to provide updated information about
veterinary products.

In 2000, Pfizer will begin including an updated Rimadyl Owner Information
Sheet which will be provided along with the prescribing information (product
insert) written for veterinarians. Similar to Patient Prescribing Information
(PPI), which is commonly distributed with pharmacy prescriptions for people,
this
owner information sheet is written in "consumer-friendly"language and provides
information about the benefits and side effects associated with NSAIDs and
Rimadyl. Like the product insert, this Owner Information Sheet will be attached
to each bottle of Rimadyl Caplets and Rimadyl Chewable Tablets. Pfizer also
plans to add this feature to other major veterinary pharmaceuticals.

Pfizer Animal Health and the FDA-CVM encourage the dispensing of prescription
products in manufacturer’s approved packaging to help ensure child
resistance, to provide complete prescribing and owner information, and maintain
quality
assurance. To better enable veterinarians to dispense full bottles, Rimadyl
Caplets will be available in 60-count and 180-count bottles like packaging
currently available for Rimadyl Chewable Tablets. (The 100 and 250 count bottles
will be discontinued as inventories are depleted.) These new bottle counts will
provide a convenient 1-month and a 3-month supply. Additionally, in 2000,
Pfizer will introduce a new 14-count trial size for Rimadyl Caplets and Rimadyl
Chewable Tablets, which contains a 7-day supply. The trial size bottles are
designed to offer a 7-day supply for new patients to help you and your clients
determine if Rimadyl is the appropriate medicine for their dog. Eventually, all
bottles will have both the prescribing information (product insert) written for
veterinarians and the new Owner Information Sheet attached as an outsert on
the outside of the bottles. Pfizer will still provide dispensing sheets if you
choose to repackage Rimadyl in some situations.

As I am sure you are aware, Pfizer Animal Health introduced Rimadyl Chewable
Tablets in June 1999. Since this introduction Pfizer has received reports of
accidental overdose in dogs and cats. Dogs, and apparently cats, are attracted
to the tablets due to the palatability. Please remind clients that Rimadyl
Chewable Tablets should be stored in a secured area out of reach of their dogs
and cats. This safety measure is outlined on the product insert as well as the
product container, and is emphasized in the Owner Information Sheet.

As part of our commitment to communicate with the veterinary community about
the safe and effective use of its products, Pfizer Animal Health recently
published an updated Technical Bulletin, entitled: Update: Two-year (1997-1998)
Clinical Experience with Rimadyl (carprofen). This update, distributed in August
1999, contains a recent summary of adverse event report information as well
as data from contemporary clinical studies. The incidence of reported possible
adverse drug events in 1998 was approximately 0.18% or 2/10ths of 1%. Some of
these side effects, like those of many other NSAID-class medications, may
occur without warning and, in rare situations, may be serious, resulting in
hospitalization or even death. Additional copies of this technical bulletin can
be
requested through Pfizer Technical Services 1(800) 366-5288 or by accessing our
website. In December 1999, FDA-CVM published their 1998 adverse drug event
report and provided an update that addresses the high number of reports in dogs
receiving Rimadyl . The data in the FDA report is consistent with the
information Pfizer previously provided to veterinarians in the August 1999
Technical
Bulletin.

In summary this communication is part of Pfizer’s continued commitment to
provide cpmplete information about the safe and effective use of its products.
Pfizer, in conjunction with the FDA-CVM, encourage veterinarians to provide
owners with information about both risks and benefits associated with all
potential therapeutic options. Pfizer is assisting veterinarians to do this by
continually updating prescribing information, providing Owner Information
Sheets, and
packaging Rimadyl in convenient trial size, 1 and 3 month supply bottles.
Please share this letter with other associates in your practice. If you have
questions or comments about the contents of this letter please feel free to
contact Pfizer Technical Service sat 1(800) 366-5288. Enclosed with this letter
is
the most current Rimadyl prescribing information and Owner Information Sheets
soon to be attached to all Rimadyl bottles. Sincerely,Edward W. Kanara, DVM,
DABVP
Director, Technical Services
Companion Animal DivisionWeb page updated by hd - March 29, 2004, 4:45 PM ET
END QUOTE


Please send your response to ClientInfoSheet@...

Jean
(Always for George - Always for the Rimadyl Dogs)

























[Non-text portions of this message have been removed]